Fulltext

Update on World Health Organization HIV Drug Resistance Prevention and Assessment Strategy: 2004-2011

Jordan, M. R. ; Bennett, D. E. ; Wainberg, M. A. ; Havlir, D. ; Hammer, S. ; Yang, C. ; Morris, L. ; Peeters, M. ; Wensing, A. M. ; Parkin, N. ; Nachega, J. B. ; Phillips, A. ; De Luca, A. ; Geng, E. ; Calmy, A. ; Raizes, E. ; Sandstrom, P. ; Archibald, C. P. ; Perriëns, J. ; McClure, C. M. ; Hong, S. Y. ; McMahon, J. H. ; Dedes, N. ; Sutherland, D. ; Bertagnolio, S.

In: Clinical Infectious Diseases, 2012, vol. 54, p. S245-S249

Aggiungi alla tua lista
    Titre
    • Update on World Health Organization HIV Drug Resistance Prevention and Assessment Strategy: 2004-2011
    Auteur
    • Jordan, M. R.. World Health Organization, Geneva, Switzerland
    • Bennett, D. E.. US Centers for Disease Control and Prevention, Atlanta, Georgia
    • Wainberg, M. A.. McGill University AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Canada
    • Havlir, D.. University of California, San Francisco
    • Hammer, S.. Columbia University Medical Center, New York, New York
    • Yang, C.. US Centers for Disease Control and Prevention, Atlanta, Georgia
    • Morris, L.. AIDS Virus Research Unit, National Institute for Communicable Diseases, Johannesburg, South Africa
    • Peeters, M.. UMI 233 TransVIHMI, Institut de Recherche pour le Développement, Montpellier
    • Wensing, A. M.. University Medical Center Utrecht, the Netherlands
    • Parkin, N.. Data First Consulting, Belmont, California
    • Nachega, J. B.. Stellenbosch University, Cape Town, South Africa
    • Phillips, A.. University College London, United Kingdom
    • De Luca, A.. Institute of Clinical Infectious Diseases, Università Cattolica del Sacro Cuore, Rome
    • Geng, E.. University of California, San Francisco
    • Calmy, A.. Médecins sans Frontière Access Campaign, Geneva
    • Raizes, E.. US Centers for Disease Control and Prevention, Atlanta, Georgia
    • Sandstrom, P.. Public Health Agency of Canada, Ottawa
    • Archibald, C. P.. Public Health Agency of Canada, Ottawa
    • Perriëns, J.. World Health Organization, Geneva, Switzerland
    • McClure, C. M.. World Health Organization, Geneva, Switzerland
    • Hong, S. Y.. Tufts University School of Medicine, Boston, Massachusetts
    • McMahon, J. H.. Tufts University School of Medicine, Boston, Massachusetts
    • Dedes, N.. International Treatment Preparedness Coalition, Bangkok, Thailand
    • Sutherland, D.. Public Health Agency of Canada, Ottawa
    • Bertagnolio, S.. World Health Organization, Geneva, Switzerland
    Type de document
    • Postprint
    Langue
    • Inglese
    Publié dans
    • Clinical Infectious Diseases, 2012, vol. 54, p. S245-S249. Oxford University Press
    Autre version électronique
    Classification
    • Santé
    Identifiant OAI-PMH
    • oai:doc.rero.ch:291440
    Summary
    The HIV drug resistance (HIVDR) prevention and assessment strategy, developed by the World Health Organization (WHO) in partnership with HIVResNet, includes monitoring of HIVDR early warning indicators, surveys to assess acquired and transmitted HIVDR, and development of an accredited HIVDR genotyping laboratory network to support survey implementation in resource-limited settings. As of June 2011, 52 countries had implemented at least 1 element of the strategy, and 27 laboratories had been accredited. As access to antiretrovirals expands under the WHO/Joint United Nations Programme on HIV/AIDS Treatment 2.0 initiative, it is essential to strengthen HIVDR surveillance efforts in the face of increasing concern about HIVDR emergence and transmission